Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.

Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res (2017) 0.75

Dendritic cells and the control of immunity. Nature (1998) 56.54

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88

Dendritic cells in a mature age. Nat Rev Immunol (2006) 5.03

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64

mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem (2004) 4.43

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature (2015) 3.46

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 3.01

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol (2010) 2.88

Memory CD4+ T cells induce innate responses independently of pathogen. Nat Med (2010) 2.61

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32

Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg (2011) 2.24

Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 2.11

Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med (2000) 2.09

Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol (2002) 1.87

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79

Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res (2000) 1.68

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol (1998) 1.64

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 1.63

Memory CD8+ T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI+ phagocytes. J Exp Med (2007) 1.40

Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol (2002) 1.40

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res (1999) 1.28

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol (2004) 1.16

Isolation and generation of human dendritic cells. Curr Protoc Immunol (2012) 1.08

The stability of human beta-globin mRNA is dependent on structural determinants positioned within its 3' untranslated region. Blood (1996) 1.06

Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 1.05

Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg (2002) 1.00

Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett (2003) 0.98

Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother (2008) 0.90

Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin Cancer Res (2005) 0.86

Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm (2012) 0.85